[14 October 2013]
Products Affected - Description
Fluticasone/Salmeterol Inhalation Aerosol
Reason for the Shortage
- GlaxoSmithKline recalled several lots of Advair HFA 45/21 inhalers in December 2012 due to particle sizes outside of specification.
- This shortage does not affect Advair Diskus inhalation powder formulations.
- This shortage does not affect Flovent (fluticasone) or Serevent (salmeterol) single-agent products.
Advair HFA Inhalation Aerosol, GlaxoSmithKline
Fluticasone 45 mcg/Salmeterol 21 mcg, 12 gram (120 doses) (NDC 00173-0715-20)
Fluticasone 45 mcg/Salmeterol 21 mcg, 8 gram (60 doses) (NDC 00173-0715-22)
Fluticasone 115 mcg/Salmeterol 21 mcg, 8 gram (60 doses) (NDC 00173-0716-22)
Fluticasone 115 mcg/Salmeterol 21 mcg, 12 gram (120 doses) (NDC 00173-0716-20)
Fluticasone 230 mcg/Salmeterol 21 mcg, 12 gram (120 doses) (NDC 00173-0717-20)
Fluticasone 230 mcg/Salmeterol 21 mcg, 8 gram (60 doses) (NDC 00173-0717-22)
Estimated Resupply Dates
All presentations are currently available.
October 14, 2013; September 30, 2013; August 27, 2013; July 25, 2013; May 28, 2013; May 17, 2013; April 22, 2013, University of Utah, Drug Information Service. Copyright 2013, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins